- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04606693
Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates (SLEEP-AF)
Value of Screening and Treatment of Sleep Apnea-Hypopnea Syndrome in the Management of Atrial Fibrillation Ablation Candidates
The present prospective cohort study (not randomized) analyses the value of screening and treatment of SAHS in the management of patients with AF refractory to antiarrhythmics drugs, potentially candidates for ablation.
Patients at low risk of suffering from SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit. Patients with high or intermediate risk of SAHS, will undergo respiratory polygraphy. If the result is positive, they will be treated as standard for this syndrome and their heart rate will be monitored for 3 months. After this, the patient's arrhythmic load will be reevaluated differentiating patients into two groups, those that must be ablated from those that have improved their condition and the clinical criteria is no longer ablation but follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients who meet all the inclusion criteria and none of the exclusion will have a Stop-Bang questionnaire to define the risk of having a SAHS The assessment of results classifies people at high, intermediate or low risk of SAHS. Low-risk patients will follow conventional management according to the usual criteria of the Arrhythmia Unit.
Patients with high or intermediate-risk will be given a Kardia© recorder and they will be instructed to obtain records of their cardiac rhythm every 5 days (at any time) and whenever the symptoms are suggestived of arrhythmia. This allows estimating arrhythmic load baseline in these patients.
They will also will be given a 7-channel home respiratory polygraphy (with pulse oximetry record, naso-buccal air flow through nasal cannula and thermistor, snoring, thoracoabdominal movements and electrocardiogram). The day after conducting the home polygraphic record, the patient will be evaluated in the Pneumology Outpatient Department, where risk factors, symptoms and Epworth's sleepiness scale will be assessed, the results of the cardiorespiratory polygraphic record, interpreted by Pneumology Service will be given , and based on the above, the diagnosis of SAHS will be determined.
Those patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
During all this time, patients will continue using their rhythm recorders as previously. The overall effect of SAHS treatment on AF recurrences (comparison of arrhythmic load in the previous 3 months with that of the 3 months post-treatment) will be evaluated.
After 3 months of starting the treatment, a follow-up respiratory polygraphy will be carried out, where the relationship between the changes in AHI and desaturation index as well as changes in arrhythmic load will be evaluated.
Once the follow-up respiratory polygraphy is performed, the indication of AF ablation will be reassessed. Patients who continue with symptomatic recurrences of AF refractory to antiarrhythmics will undergo ablation.
It will be analyzed that proportion of patients initially candidates for ablation cease to fulfill conditions for this by a better control of recurrences and "leave the waiting list". Likewise, the results of the ablation of the cohort of patients diagnosed with SAHS and the moderate or high-risk cohort of SAHS, but with negative polygraphy and diagnosis, will be compared.
The arrhythmic load after AF ablation will be analysed, during the blinding period (3 months post-ablation) and one year after the ablation. Patients will continue their SAHS treatment according to the usual practice of the Pneumology Service.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nicasio Pérez-Castellano, MD PhD
- Phone Number: 7278 +34913303000
- Email: nicasio.perez@salud.madrid.org
Study Locations
-
-
-
Madrid, Spain, 28040
- Recruiting
- Hospital Clinico San Carlos
-
Contact:
- Nicasio Pérez-Castellano, MDhPhD
- Phone Number: 7278 +34913303000
- Email: dr.npc.clinical.trials@gmail.com
-
Sub-Investigator:
- Norberto Torres-Esquivel, MD
-
Sub-Investigator:
- María-Jesús García-Torrent, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with paroxysmal or persistent atrial fibrillation
- Recurrent atrial fibrillation despite treatment with at least one class I or III antiarrhythmic
- No previous diagnosis of apnea-hypopnea syndrome
Exclusion Criteria:
- Patients <18 years
- Pregnant women
- Doubts about the patient's ability to perform a home respiratory polygraphy
- Doubts about the patient's ability to acquire rhythm records with the Kardia system (smartphone required)
- Unavailability for follow-up at our center for at least 1 year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Patients with negative diagnosis of SAHS
Patients with low risk or negative diagnosis of SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit
|
|
Other: Patients with positive diagnosis of SAHS
Patients with intermediate or high risk of SAHS and positive diagnosis
|
Patients diagnosed with SAHS will be treated in the Pneumology Service according to usual practice (dietary hygienic measures, CPAP, etc.).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arrhythmic load
Time Frame: Six months
|
Rate of time in FA measured with Kardia © recorder
|
Six months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20/023-E
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation, Persistent
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
University of LuebeckIHF GmbH - Institut für HerzinfarktforschungRecruitingPersistent or Long-standing Persistent Atrial FibrillationGermany
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...RecruitingPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationChina
-
University Medical Centre LjubljanaWithdrawnPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationSlovenia
-
AtriCure, Inc.CompletedPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationUnited States
-
Medtronic Bakken Research CenterTerminatedLongstanding Persistent Atrial FibrillationSpain, Germany, Israel, Italy
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
Medtronic Cardiac SurgeryRecruitingPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationUnited States
Clinical Trials on Treatment of SAHS
-
Hospital Clinic of BarcelonaCompleted
-
Sahlgrenska University Hospital, SwedenVastra Gotaland RegionRecruiting
-
Lund UniversityCompletedBest Medical Treatment | Superficial Femoral Artery Disease | Stable Claudication (Fontaine IIa and IIb) | Quality of Life Scores at 12 and 24 MonthsSweden
-
Assistance Publique - Hôpitaux de ParisVaincre la MucoviscidoseCompletedBack Pain | Chest Pain | Neck Pain | Cystic FibrosisFrance
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Stanford UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Stanford UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruiting
-
Assistance Publique - Hôpitaux de ParisWithdrawn
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruiting
-
Guang'anmen Hospital of China Academy of Chinese...UnknownKnee OsteoarthritisChina